SCHEMBL20119907

SCHEMBL20119907

COc1nc2c(NCc3ccncc3)nc(Cl)nc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
PGK1 P00558 1/20 0.43
PDE5A O76074 4/20 0.43
CDK1 P06493 2/20 0.39
PDE10A Q9Y233 2/20 0.39
APP P05067 1/20 0.37
YTHDC1 Q96MU7 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PDE6D O43924 1/20 0.35
PDE6A P16499 1/20 0.35
PDE6G P18545 1/20 0.35
PDE6B P35913 1/20 0.35
PDE6C P51160 1/20 0.35
PDE6H Q13956 1/20 0.35
TGFBR1 P36897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119522 0.88 CDK1 (0.40) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119916 0.87 CCNE1 (0.40) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119456 0.87 CDK1 (0.40) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119867 0.86 CDK2 (0.40) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119611 0.86 CDK1 (0.39) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119503 0.85 CDK2 (0.40) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119530 0.83 CDK1 (0.37) CCNE2CCNE1CDK2PDE5ACDK1
SCHEMBL20119803 0.83 CDK2 (0.36) CCNE2CCNE1CDK2PGK1PDE5A
SCHEMBL20119728 0.82 CCNE2 (0.41) CCNE2CCNE1CDK2PDE5ACDK1
SCHEMBL20119546 0.82 CDK2 (0.36) CCNE2CCNE1CDK2PGK1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CCNE2 4321/4885CCNE1 4220/4885CDK2 3622/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CCNE2 4321/4885CCNE1 4220/4885CDK2 3622/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CCNE2 4321/4885CCNE1 4220/4885CDK2 3622/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CCNE2 4321/4885CCNE1 4220/4885CDK2 3622/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CCNE2 4321/4885CCNE1 4220/4885CDK2 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.